Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Acronyms CHECKMATE 920
- Sponsors Bristol-Myers Squibb
- 22 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 18 Jan 2018 Planned End Date changed from 5 Jan 2023 to 28 Feb 2023.
- 16 Feb 2017 Planned primary completion date changed from 1 Jan 2023 to 1 Mar 2018.